Your English writing platform
Discover LudwigSuggestions(1)
Exact(1)
Based on publicly-available information, we estimate that our data capture 27% of purchases from Brazil, South Africa, and Thailand and therefore represent the vast majority of ARV purchases in developing countries.
Similar(59)
According to the Office of the High Commissioner for Human Rights, 89% of 2010 supplies to donor-funded HAART programmes were Indian generics[ 4- 6], alongside 80% of the ARVs used by Médecins Sans Frontières and the majority of ARVs supplied through the US government's PEPFAR programme[ 7].
We needed to assume a 20% and a 40% lower API cost for our model to predict that publicly owned and Indian manufacturers, respectively, would make profits on the sale of the majority of their ARVs.
Currently there are approximately 14,000 children living with HIV in Thailand, and the majority of them receive ARVs.
The majority of patients enrolled were ARV-naïve, HIV-infected women (see Table 1).
The σC and σB proteins of ARV are known to elicit neutralizing antibodies against ARV.
This result poses questions on the issue of adherence to ART for patients who were already on ART prior to MDR-TB treatment in a country like South Africa with majority of HIV positive patients on ARVs.
Majority 533 (86%) of the patients received the first dose of ARV within the recommended 48 hours.
However, despite these encouraging stories, the majority of participants who were not on ARVs did not want to start taking ARVs because they were concerned about side effects and the burden on the daily regimen.
The majority of HIV-positive women were antiretroviral (ARV) naïve (93.4%).
In regards to the importance of being a PEPFAR priority country, the data indicate that PEPFAR priority countries were in the majority of cases not associated with the ARV price; only in the cases of didanosine 400 mg and lopinavir/ritonavir PEPFAR focus countries were paying more and the case of lamivudine/zidovudine they were paying less.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com